Thank you.
My question is directed to you, Mr. Eisenschmid.
Here at committee we've heard from a number of groups of witnesses—academics and industry, individuals and representatives—and many of them have pointed a finger at pharmacists for higher drug prices. The Pharmacare 2020 academics even went so far as to question the credibility of your organization to conduct research and picked on some of the statistics you brought forward, indicating that your conclusions were motivated by profit margins rather than other alternatives.
I can imagine these allegations are familiar to you. I'm actually just looking for you to comment on those allegations today.